Back to results
US 12,559,455 B2Granted
Compound as a UBR box domain ligand
AssigneeAutotac Inc.
InventorsYong Tae Kwon, Hyun Tae Kim, Jeong Eun Na, Yu Jin Seo, Chang Hoon Ji, Ha Rim Choi, Ji Eun Lee, Ah Jung Heo
Life of this patent
Estimating the term…
Abstract
The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.
Claims10
A compound or a salt thereof,
- wherein the compound is selected from the group consisting of:
- 4-amino-N′-(4-hydroxybenzoyl)benzenesulfonohydrazide;
- 4-amino-N′-(4-hydroxybenzoyl)-3-morpholinobenzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl)-2-oxoindoline-5-sulfonohydrazide;
- N′-(4-hydroxybenzoyl) indoline-5-sulfonohydrazide;
- N′—([1,1′-biphenyl]-4-carbonyl)-4-aminobenzenesulfonohydrazide;
- N′—([1,1′-biphenyl]-3-carbonyl)-4-aminobenzenesulfonohydrazide;
- 3-amino-N′-(4-hydroxybenzoyl)benzenesulfonohydrazide;
- 4-(1-aminoethyl)-N′-(4-hydroxybenzoyl)benzenesulfonohydrazide;
- 3,5-diamino-N′-(4-hydroxybenzoyl)benzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl)-4-((2-hydroxyethyl)amino)benzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl)-4-methoxybenzenesulfonohydrazide;
- 4-((2-(4-hydroxybenzoyl)hydrazinyl)sulfonyl)benzimidamide;
- 4-((2-(4-hydroxybenzoyl)hydrazinyl)sulfonyl)benzamide;
- 6-amino-N′-(4-hydroxybenzoyl)-[1,1′-biphenyl]-3-sulfonohydrazide;
- 4-(2-((4-aminophenyl)sulfonyl)hydrazine-1-carbonyl)benzamide;
- 4-amino-N′-(1H-indole-3-carbonyl)benzenesulfonohydrazide;
- 4-amino-N′-(4-hydroxybenzoyl)-3-(pyrrolidin-1-yl)benzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl)-4-nitro-3-(pyrrolidin-1-yl)benzenesulfonohydrazide;
- 4-amino-N′-(4-hydroxybenzoyl)-3-(piperidin-1-yl)benzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl)-1H-pyrazole-4-sulfonohydrazide;
- N′-(4-hydroxybenzoyl) indoline-4-sulfonohydrazide;
- N′-(4-hydroxybenzoyl)-1H-indole-4-sulfonohydrazide;
- 4-amino-N′-(1H-indole-4-carbonyl)-3-morpholinobenzenesulfonohydrazide;
- 4-amino-N′-(indoline-4-carbonyl)benzenesulfonohydrazide;
- 4-amino-N′-(4-hydroxybenzoyl)-3-(piperazin-1-yl)benzenesulfonohydrazide;
- 4-amino-N′-(2,3-dihydro-1H-indene-2-carbonyl)benzenesulfonohydrazide;
- 4-amino-N′-(isoindoline-2-carbonyl)benzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl)-1H-indole-2-sulfonohydrazide;
- 4-amino-N′-(2-phenylacetyl)benzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl)-1H-indazole-3-sulfonohydrazide;
- 4-amino-N′-(indoline-6-carbonyl)benzenesulfonohydrazide;
- 4-amino-N′-(indoline-3-carbonyl)benzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl) piperidine-4-sulfonohydrazide;
- 4-amino-N′-(indoline-6-carbonyl)-3-morpholinobenzenesulfonohydrazide;
- 4-amino-N′-(piperazine-1-carbonyl)benzenesulfonohydrazide;
- 4-amino-3-morpholino-N′-(piperazine-1-carbonyl)benzenesulfonohydrazide;
- N′-(4-hydroxybenzoyl)-2-methylthiazole-4-sulfonohydrazide;
- (1S,4S)-4-amino-N′-(4-hydroxybenzoyl)cyclohexane-1-sulfonohydrazide;
- (1R,4R)-4-amino-N′-(4-hydroxybenzoyl)cyclohexane-1-sulfonohydrazide;
- 4-((2-(4-hydroxybenzoyl) hydrazinyl) sulfonyl)-5-methylfuran-2-carboxylic acid;
- N′-(4-hydroxybenzoyl) pyrrolidine-3-sulfonohydrazide;
- N′-(4-hydroxybenzoyl)-1H-pyrrolo[2,3-b]pyridine-2-sulfonohydrazide;
- 2-((4-aminophenyl) sulfonyl)-N-(3-hydroxyphenyl) hydrazine-1-carboxamide;
- and
- 2-((4-amino-3-morpholinophenyl) sulfonyl)-N-phenylhydrazine-1-carboxamide.
43 more elements
A method for treating UBR related disease, the method comprising:
- administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound or a salt thereof, wherein the compound has the structure of formula 1-1:
- wherein X1 is an optionally substituted with one or more R2 or unsubstituted phenyl, cycloalkyl or heterocyclyl;
- each R2 is independently selected from alkyl, alkoxy, amino, aminoalkyl, —NO2, ═O, —NHC2H4OH, —C(═NH)NH2, —C(═O)NH2, —C(═O)NHCH3, —C(═O)OH, phenyl or heterocycloalkyl;
- X4 is an optionally substituted with one or more R3 or unsubstituted phenyl, cycloalkyl or heterocylyl;
- each R3 is independently selected from alkyl, alkoxy, amino, halo, hydroxyl, alkylamino, dialkylamino, —NO2, —CONR′R″, —CO2R′, —NHCOR′, phenyl or heterocycloalkyl;
- each R′ and R″ is independently-H or alkyl;
- A1 is CH2 or NH;
- and
- I is an integer of 0 or 1.
6 more elements
A method for binding a compound or a salt thereof to a UBR box domain in a subject, the method comprising:
- administering a composition comprising the compound or the salt thereof, wherein the compound has the structure of formula 1-1:
- wherein the X1 is an optionally substituted with one or more R2 or unsubstituted phenyl, cycloalkyl or heterocyclyl;
- each R2 is independently selected from alkyl, alkoxy, amino, aminoalkyl, —NO2, ═O, —NHC2H4OH, —C(═NH)NH2, —C(═O)NH2, —C(═O)NHCH3, —C(═O)OH, phenyl or heterocycloalkyl;
- X4 is an optionally substituted with one or more R3 or unsubstituted phenyl, cycloalkyl or heterocylyl;
- each R3 is independently selected from alkyl, alkoxy, amino, halo, hydroxyl, alkylamino, dialkylamino, —NO2, —CONR′R″, —CO2R′, —NHCOR′, phenyl or heterocycloalkyl;
- each R′ and R″ is independently-H or alkyl;
- A1 is CH2 or NH;
- and
- I is an integer of 0 or 1.
6 more elements
Dependencies are inferred from the claim text.